Pacira BioSciences' Common Equity fell 2.98% to $727.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $727.2 million, marking a year-over-year decrease of 2.98%. This contributed to the annual value of $778.3 million for FY2024, which is 10.55% down from last year.
Pacira BioSciences' Common Equity amounted to $727.2 million in Q3 2025, which was down 4.03% from $757.8 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Common Equity ranged from a high of $892.2 million in Q1 2024 and a low of $650.8 million during Q1 2021.
In the last 3 years, Pacira BioSciences' Common Equity had a median value of $798.5 million in 2025 and averaged $805.5 million.
As far as peak fluctuations go, Pacira BioSciences' Common Equity surged by 77.04% in 2021, and later dropped by 13.82% in 2025.
Quarterly analysis of 5 years shows Pacira BioSciences' Common Equity stood at $730.4 million in 2021, then climbed by 6.11% to $775.0 million in 2022, then climbed by 12.27% to $870.1 million in 2023, then decreased by 10.55% to $778.3 million in 2024, then declined by 2.98% to $727.2 million in 2025.
Its Common Equity stands at $727.2 million for Q3 2025, versus $757.8 million for Q2 2025 and $798.5 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value